In the United Kingdom, the prevalence of growth hormone deficiency is reported to be between 1 in 4 000 and 1 in 10 000 (I). Although most cases are sporadic and believed to result from exogenous cerebral insults or developmental abnormalities, 5-30% of GH-deficient patients have a GH-deficient relative; therefore, in these cases the disorder is suggested to be mainly familial (2) . Four distinct familial types of IGHD have been defined on the basis of inheritance and other hormone deficiencies (3) . This classification includes IGHD type IA, autosomal recessive with absent endogenous GH; type IB, autosomal recessive with diminished GH; type 11, autosomal dominant with diminished GH; and type 111, X-linked with diminished GH.
domains of the GHRH receptor gene were performed. None of the analyses revealed any structural abnormalities in these patients with IGHD. This suggests that a lit/lit mouse equivalent is an unlikely explanation for the majority of children with IGHD. Although gross structural abnormalities in the whole gene have been ruled out in this study, mutations in the carboxyl terminus are still possible, and, therefore, the remaining part of the gene needs to be sequenced. (Pediatr Res 38: 962-966, 1995) Abbreviations IGHD, isolated GH deficiency GH, growth hormone r-hGH, recombinant hGH GHRH, growth hormone releasing hormone &/lit mouse, little/little mouse PCR, polymerase chain reaction RFLP, restriction fragment length polymorphism Although most cases of IGHD type IA are due to homozygous deletions of the GH-1 gene encoding the pituitary-derived GH, kindreds with IGHD have been recently reported in whom two distinct point mutations caused a nonsense and splicing defect affecting the hGH-1 gene (4). The loci and mutations responsible for other Mendelian forms of IGHD still remain unknown (3, 5) , but linkage studies have excluded the GH-1 locus in more than 50% of the autosomal IGHD (types IB and 11) families in which the genetic defect causing the IGHD phenotype segregated independently of the GH gene (5, 6) . The regulation of GH secretion is complex, and there are, therefore, multiple sites at which a genetic defect may perturb homeostasis, resulting in GH deficiency and short stature. Mutational changes in genes that are specifically related to GH would be Since Mayo cloned the human pituitary-specific receptor for GHRH and a homozygous mutation within the GHRH binding domain of the receptor was described to be the molecular basis of the defect in the lit/lit mouse, an animal model of autosomal recessive isolated GH deficiency, the GHRH receptor gene has become a testable candidate gene for IGHD (8, 9) (Fig. 1) . Thus, the aim of the present study was to screen the GHRH receptor gene for structural alterations in patients suffering from short stature classified as IGHD.
METHODS

Patients.
DNA from 65 unrelated healthy Caucasians of normal stature (10) were studied as controls. In addition, 65 children with IGHD type IB attending the Growth Disorder Clinic either at the Middlesex Hospital in London or at the University Children's Hospital in Bern, Switzerland, were studied. The parents of the affected children studied were normal for height and sex (10) . Children from Mediterranean, Asian, African, and Semitic descent were excluded from the study. The criteria for IGHD type IB included no demonstrable causes for IGHD including GH-gene cluster abnormalities, short stature 52.5 SDS, decreased growth rate, retarded bone age, normal karyotype, normal thyroid function, and peak GH levels below 4 pg/L after stimulation test (insulin-induced hypoglycemia). Details of the patients are given in Table 1 . Twelve children were treated with exogenous GHRH for a 6-mo period, but did not respond at all. Either twice daily s.c. injections (25 pglkgld) of GHRH (1-29)-NH, or GHRH (1-40) S.C. by a pulsatile pump at 3-h intervals, over a 12-h period at night, at a dose of 1-2 pglkglpulse were administered. Data are presented in Table 2 . Standard auxologic assessment was performed (11) . No child had evidence of organic disease, psychosocial deprivation, or any eating disorder, and all had normal renal and hepatic function. All children showed a sustained response to r-hGH treatment over 1-10 y (median 4.8 y).
Preparation of the DNA. Genomic DNA was isolated from peripheral leukocytes and from EBV-transformed lymphoblasts as previously described (6, 12) . The concentration of each sample was determined by measuring the OD of the purified DNA at 260 and 280 nm.
Restriction endonuclease digestion and Southern blotting. Samples of DNA (5 pg) were digested to completion with BamHI and the restriction enzymes shown in Table 3 . After electrophoresis in 0.5-1.2% (wtlvol) agarose gel, the DNA fragment were transferred onto a nylon membrane (Hybond-N, Amersham, Rahn Zurich, Switzerland) and hybridized to the GHRH receptor cDNA probe. HPR3Z is a 1.6-kb human GHRH receptor cDNA clone described by Mayo (9) inserted into pGEM7Z as previously described (9, 13) . The filters were then washed at 65OC and autoradiographed at -70°C using intensifying screens (6, 12, 13) .
PCR amplification of the extracellular binding domain of the GHRH receptor. Gene fragments coding for the extracellular binding domain of the GHRH receptor were PCRamplified in patients and controls (14) . One microgram of genomic DNA was added to 100 p L of reaction mixture of 10 mM Tris-HC1 (pH 8.3), 50 mM KC1, 1.5 mM MgCl,, 0.1% Triton X-100, 200 mM of each deoxy-NTP, 0.1 mM of each primer, and 4 U of Taq DNA polymerase (Boehringer Mannheim, Rotkreuz, Switzerland). The up-and down-stream primers corresponded to nucleotides 188-206 (sense: 5 ' -GGAGATGCCCAACACCAC-3') and 773-790 (antisense: 5'-GAACCAGCCACCAGAAGG-3') covering approximately 600 bp (9) . The PCR reaction mixture (without Taq DNA polymerase) was denatured for 6 min at 94°C and 4 U of Taq DNA polymerase were added at 80°C. Then the solution was cycled 35 times (94"C, 1.0 min; 63"C, 1.0 min; 72°C 1.5 min), followed by a 10-min extension at 72°C.
Restriction endonuclease detection of mutations. Aliquots of PCR amplification products were digested with the enzymes shown in Table 4 . The enzymes FokI was chosen because the mutation in the lit/lit mouse on codon 60 is from GAT (Asp) to GGT (Gly) (8, 9, 15) which destroys the FokI restriction site (GGATGN).
DNA sequencing. The PCR products were cleaned by filtration with Qiaquick PCR purification kit (Qiagen, Hilden, Germany), then digested with different enzymes and correspondingly cloned into a PCR 1000 vector (Invitrogen Corp. BV, NV Leek, The Netherlands). The cloned GHRH receptor PCR products were purified from an overnight culture by the alkaline lysis method (16), followed by digestion with 4 U of RNase (Sigma Chemical Co. Chemie, Buchs SG, Switzerland) and precipitation by addition of an equal volume of a 1.6 M NaCl 13% polyethylene glycol solution. The plasmid DNA was then sequenced by the dideoxy method (17) using dsDNA cycle sequencing system (Boehringer Mannheim; MWG-Bio Tech AG, Munchenstein, Switzerland). The median is given in parentheses. Vel., velocity; SDS, standard deviation score * Total base pairs screened = (no. of base pairs in restriction site) X (no. of bands -1) X (no. of chromosomes screened).
RESULTS
PCR ampliJication of the extracellular binding domain of
Restriction endonuclease digestion and Southern blotting. The GHRH receptor cDNA probe was used to examine sets of chromosomes of healthy subjects and children with IGHD to check for gross gene abnormalities. No mutation was found (Table 3) having screened a total of 91.26 X lo6 bp.
Linkage analysis. Linkage analysis was performed using the BamHI RFLP for the GHRH receptor locus we reported previously in controls (13) . The distribution of the alleles were identical in all three groups, controls, children with IGHD, and children with IGHD who did not respond to GHRH treatment (Table 5) . the GHRH receptor. Using the primers described, genomic PCR fragments were obtained and screened for gross alterations by restriction enzyme analysis (Table 4) . However, no alteration could be found and the FokI digestion pattern in controls and patients was identical suggesting that in our children with IGHD who did not respond to the GHRH treatment not the same mutation as in the lit/lit mouse found is present.
DNA sequencing. DNA from the children who did not respond to GHRH treatment spanning from exon 2 to 7 was sequenced. Neither a mutation nor a deletion was found when compared with sequences obtained from the control population (8, 9). (24) the synthesis and secretion of GH from pituitary somatotroph
Numbers of chromosomes analyzed are in parentheses.
after its binding to the GHRH receptor (18) (19) (20) . The recent identification and cloning of a receptor for GHRH has allowed to study its role in the etiology of growth disorders to be examined (8, 9, 21) . The GHRH receptor is a 423-amino acid protein that contains the seven membrane-spanning domains characteristic of G protein-coupled receptors ( Fig. 1) (8) .
The phenotype of IGHD type IB in humans has much in common with the phenotype of homozygous lit/lit mice including autosomal recessive inheritance, time of onset of growth retardation, diminished secretion of GH and IGF-I, proportional reduction in weight and skeletal size, and delay in sexual maturation (22) (23) (24) (25) . Sequencing of the GHRH receptor gene in lit/lit mice has shown a single nucleotide substitution in codon 60 that changed aspartic acid to glycine (8) . This substitution in the extracellular binding domain prevents GHRH binding to the receptor (8) . Therefore, GHRH receptor would appear to be a reasonable candidate gene for mutation in patients with IGHD. The aim of the study was to screen the extracellular domain for mutations which may, first, cause short stature in patients with IGHD and, second, explain the nonresponsiveness to GHRH treatment in a more specific group of IGHD patients.
As with any new candidate gene, Southern blot analysis was performed to screen for gross deletions and for informative RFLPs followed by linkage analysis. As shown in Table 3 and 5, neither restriction enzyme analysis nor the linkage analysis were successful in defining any GHRH receptor abnormality. Thereafter, PCR amplification of the extracellular domain of the GHRH receptor was performed. Following the known pattern of the mouse GHRH receptor we amplified from amino acid 47 to 240 including exon 3 which contains the lit/lit mutation, exon 4 to 6 and part of exon 2 and 7. These exons encode the extracellular domain and the first three membrane spanning loops (Fig. 1) (8) . Restriction enzyme pattern and sequence analysis were identical in controls and patients with IGHD and, therefore, no structural abnormalities as described in the lit/lit mice were found in the extracellular binding domain which would explain first the phenotype of IGHD IB and second the nonresponse to GHRH treatment in some of these patients.
However, we did not sequence exons 8-13 which encode the remaining 4 membrane spanning domains and the intracellular domains. In humans, the exon and intron boundaries in that region are still unknown, and further sequencing of the genomic GHRH receptor in all these patients will be important as several recent examples underscore the potential involvement of G protein-coupled receptor in inherited diseases or phenotypic variations. In congenital nephrogenic diabetes insipidus for instance, several different mutations within the vasopressin V2 receptor have been described (26) (27) (28) . In addition, recently thyroid dysfunctions have been reported by Sunthornthepvarakul et al. (29) caused by mutations within the extracellular domain of the TSH receptor gene resulting in TSH resistance.
Patients with a phenotype of IGHD type IB who do not respond to GHRH treatment but show a growth promoting effect on r-hGH therapy may have a defect in the GHRH receptor signaling pathway. Such a defect could theoretically occur anywhere in the signaling cascade, from the receptor to the molecules activating adenylate cyclase including Gs subtypes of G proteins. Additionally, in several cell types elevated CAMP leads to the phosporylation and activation of transcription factor CREB by protein hnase A (30, 31) . One target for CREB action is the 5' up-stream region of the hGH-1 gene which regulates expression of the GH gene in somatotroph cells, thus providing a pathway by which GH expression is regulated.
To summarize, we have studied the extracellular domain of the GHRH receptor (introns, exons 2-7) in 65 healthy controls and in 65 patients phenotypically classified as having IGHD type IB. Any GH gene cluster abnormalities were excluded. In addition, DNA from 12 patients growing well on r-hGH replacement therapy but who did not respond to GHRH treatment were studied. Neither restriction enzyme analysis, linkage analysis, nor sequencing data revealed any structural abnormalities in these patients excluding the possibility of a lit/lit mouse equivalent in humans. Although gross structural abnormalities in the whole gene have been ruled out in our study, mutations in the carboxyl terminus are still possible and, therefore, the whole gene including introns will need to be sequenced.
